Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-36294 uniQure N.V. (Exact name of Registrant as specified in its charter) The Netherlands Not a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-36294 uniQure N.V. (Exact name of Registrant as specified in its charter) The Netherlands Not ...

Charles, Huntington's disease patient advocate LE A D E R S H IP IN GE N E T H E R A P Y LEADERSHIP IN GENE THERAPY MARCH 2023 MA R C H 2023 | 22 First approved AAV gene therapy First AAV vector demonstrated effective in patients with NABs MARCH 2023 a case study in delivering value through innovation 2017 Announced transition to AMT-061 2018 Initiated Ph 2b doseconfirmation study and HOPE-B pivotal study leading the gene therapy revolution • Broad pipeline of first/best-in-class gene therapies • EU approva ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36294 uniQure N.V. (Exact name of Registrant as specified in its charter) The Netherlands (Jurisdiction of incorpor ...

| --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------|-------|-------|----------------------------------------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Leadership in | | | | | | | | | Gene Therapy | | | | | | | | | Corporate Presentation September 2021 | Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements of historical fact are forward- looking statements, w ...

| --- | --- | --- | --- | --- | --- | |----------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | A Global Leader in Gene Therapy | | | | | | | Corporate Presentation | | | | | | | November 2020 | | | | | | uniQure A G L O B A L L E A D E R I N G E N E T H E R A P Y N O V E M B E R 2020 | 2 Forward-looking Statements This presentation contains forward-looking statements. All statements other than statement ...

| --- | --- | --- | --- | --- | --- | |----------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | A Global Leader in Gene Therapy | | | | | | | | | | | | | | Corporate Presentation | | | | | | | September 2020 | | | | | | uniQure A G L O B A L L E A D E R I N G E N E T H E R A P Y S E P T E M B E R 2 0 2 0 | 2 Forward-looking Statements This presentation contains forward-looking statements. All statements ...

| --- | --- | --- | --- | --- | |-------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | Global License Agreement in Hemophilia B | | | | | | June 24, 2020 | | | | | | | | | | | | | | | | | Forward-looking Statements A G L O B A L L E A D E R I N G E N E T H E R A P Y J A N U A R Y 2 0 2 0 | 2 This presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, whi ...

| --- | --- | --- | --- | --- | --- | |------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | A Global Leader in | | | | | | | Gene Therapy | | | | | | | Corporate Presentation | | | | | | | April 2020 | | | | | | uniQure A G L O B A L L E A D E R I N G E N E T H E R A P Y A P R I L 2 0 2 0 | 2 Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements ...

| --- | --- | --- | --- | --- | --- | |----------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | A Global Leader in Gene Therapy | | | | | | | Corporate Presentation | | | | | | | March 2020 | | | | | | uniQure A GLOBAL LEADER IN GENE THERAPY MARCH 2020 | 2 Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements of historical fact are forward- ...